Matthew C. Ward, MD, a radiation oncologist with the Southeast Radiation Oncology Group, discusses the use of adjuvant radiation in prostate cancer, including a comparison of adjuvant radiotherapy and early salvage radiotherapy.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.